¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2024-03-08

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2024-03-08
±³À°ÀÏÀÚ : 2024-03-08
±³À°Àå¼Ò : ´ëÀüÄÁº¥¼Ç¼¾ÅÍ

±³À°ÁÖÁ¦ : 2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇÑ°©»ó¼±ÇÐȸ
´ã´çÀÚ : ÀÌÀçÀº
¿¬¶ôó : 02-743-0320  

À̸ÞÀÏ : office@thyroid.kr

±³À°Á¾·ù : ³»°ú, ¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, º´¸®°ú, ÇÙÀÇÇаú

Âü¼®¿¹»óÀÎ : 350¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : ´ëÀü±¤¿ª½Ã
±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 120,000¿ø  

ºñ°í " 1. Àü¹®ÀÇ/ÀϹÝÀÇ 1) Æò»ýȸ¿ø ¹× Á¤È¸¿ø(¿¬È¸ºñ ³³ºÎÀÚ) »çÀüµî·Ï 90,000¿ø, ÇöÀåµî·Ï 110,000¿ø, 2) ºñȸ¿ø »çÀüµî·Ï 100,000¿ø, ÇöÀåµî·Ï 120,000¿ø 2. Àü°øÀÇ/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/°£È£»ç/±âÃÊÀÇÇÐÀÚ 1) Æò»ýȸ¿ø ¹× Á¤È¸¿ø(¿¬È¸ºñ ³³ºÎÀÚ) »çÀüµî·Ï 50,000¿ø, ÇöÀåµî·Ï 70,000¿ø, 2) ºñȸ¿ø »çÀüµî·Ï 70,000¿ø, ÇöÀåµî·Ï 90,000¿ø 3. ¸¸65¼¼ ÀÌ»óÀÎ Æò»ýȸ¿ø, Çкλý ¹× ÀÇÀü¿ø Çлý : ¹«·á"


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 13:00~13:20 Oncocytic tumor: Radiologic perspective ÇѼö¿¬(¼º±Õ°üÀÇ´ë ¿µ»óÀÇÇаú)

±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 13:20~13:40 Pathologic perspectives ½ÅÇüÂù(°è¸íÀÇ´ë º´¸®°ú)

±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 13:40~14:00 Clinical perspectives ±è¼ö¿µ(¾ÆÁÖÀÇ´ë ¿Ü°ú)

Åä·Ð 03¿ù 08ÀÏ 201È£ 14:00~14:10 Discussion ()

±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 14:10~14:30 Appropriate RAI treatment strategies for low-intermediate risk DTC ±èÈñ°æ(Àü³²ÀÇ´ë ³»°ú)

±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 14:30~14:50 Risk and benefits of high-dose RAI treatment for advanced DTC ¿À¼Ò¿ø(¼­¿ïÀÇ´ë ÇÙÀÇÇаú)

±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 14:50~15:10 Defining RAI refractory thyroid cancer & when to start TKI treatment ±è¿ø±¸(¿ï»êÀÇ´ë ³»°ú)

Åä·Ð 03¿ù 08ÀÏ 201È£ 15:10~15:20 Discussion ()

ÈÞ½Ä 03¿ù 08ÀÏ 201È£ 15:20~15:40 Coffee Break ()

±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 15:40~16:20 ±×·¹À̺꽺º´ÀÇ Ä¡·á½Ã Ç×°©»ó¼±Á¦ »ç¿ë ¼Û¿µ±â(¶¯Å¥¼­¿ïÀÇ¿ø ³»°ú)

±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 16:20~16:40 Early Rehabilitation after Thyroid Surgery ¹ÚÁø¿µ(¿¬¼¼ÀÇ´ë ÀçÈ°ÀÇÇаú)

±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 16:40~17:00 Psychosocial Support for Thyroid Cancer Survivors Á¶ÁÖÈñ(¼º±Õ°ü´ëÇб³ »ï¼ºÀ¶ÇÕÀÇ°úÇпø)

±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 17:00~17:20 Nutrition Care after Thyroid Cancer Surgery °­ÀºÈñ(¼­¿ï¾Æ»êº´¿ø ¿µ¾çÆÀ)

Åä·Ð 03¿ù 08ÀÏ 201È£ 17:20~17:30 Discussion ()

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 13:00~13:10 [±¸¿¬¹ßÇ¥] Long-Term Clinical Outcomes and Prognostic Factors of Medullary Thyroid Carcinoma Over 30 Years "¿À¹®¿µ (¼­¿ïƯº°½Ãº¸¶ó¸Åº´¿ø ¿Ü°ú)"

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 13:10~13:20 [±¸¿¬¹ßÇ¥] A Protein Tumor Marker in Fine Needle Aspiration Washout Fluid: Insights from a Dual Cohort Analysis of Thyroid Cancer Patients "ÀÌÁ¤¹Î (°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ³»°ú)"

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 13:20~13:30 [±¸¿¬¹ßÇ¥] Endotrophin promotes tumor growth by supporting immune-suppressive hypoxic microenvironments in anaplastic thyroid cancer "±èÀ¯Çü (¼­¿ï´ëÇб³º´¿ø ³»ºÐºñ³»°ú)"

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 13:30~13:40 [±¸¿¬¹ßÇ¥] Performance enhancement of a heart rate-based thyrotoxicosis prediction machine learning-assisted system through reference to multiple TFT Results "½Å±Ôº¸ (ÁÖ½Äȸ»ç ŸÀ̷νºÄÚÇÁ)"

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 13:40~13:50 [±¸¿¬¹ßÇ¥] In Graves' disease surgery, goiter size may be more important than the patient's preoperative euthyroid status "À¯ÁöÇö (»ï¼º¼­¿ïº´¿ø ³»ºÐºñ´ë»ç³»°ú)"

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 13:50~14:00 [±¸¿¬¹ßÇ¥] Highly Targeted TERT Mutation Detection in Thyroid Cancer Through Digital Droplet PCR "ÀÌÁ¤¹Î (°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ³»°ú)"

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 14:10~14:20 [±¸¿¬¹ßÇ¥] Selenium Efficacy in Mild-to-Moderate Graves¡¯ Ophthalmopathy within Selenium-Sufficient Regions (SeGOSS Trial): A Phase III, Multicenter, Open-Label, Randomized, Controlled Intervention Study "ÀåÁø¼± (¼­¿ï´ëÇб³º´¿ø ³»ºÐºñ³»°ú)"

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 14:20~14:30 [±¸¿¬¹ßÇ¥] Prognosis of patients with brain metastases of differentiated thyroid carcinoma "±èä¾Æ (¼­¿ï¾Æ»êº´¿ø ³»ºÐºñ³»°ú)"

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 14:30~14:40 [±¸¿¬¹ßÇ¥] Utilizing IgG4 Immunohistochemistry for Risk Stratification in Patients with Papillary Thyroid Carcinoma Associated with Hashimoto Thyroiditis "Á¤Âù±Ç (¼­¿ï¼º¸ðº´¿ø º´¸®°ú)"

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 14:40~14:50 [±¸¿¬¹ßÇ¥] Validation of Glandy CAS Software in the Assessment of Thyroid Eye Disease Activity: A Confirmatory Clinical Trial "±èÁ¾Âù (ÁÖ½Äȸ»ç ŸÀ̷νºÄÚÇÁ)"

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 14:50~15:00 [±¸¿¬¹ßÇ¥] Metastatic lymph node with ultrasonographic punctate echogenic foci (PEF) harbors PEF in primary thyroid cancer "¹Ú¼ö¸° (°Ç±¹´ëÇб³ ÀÇ°ú´ëÇÐ ÇÙÀÇÇаú)"

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 15:00~15:10 [±¸¿¬¹ßÇ¥] 10-year follow-up of radiofrequency ablation of benign thyroid nodule: perspective on technical outcome "½ÅÀçÈ£ (°í·Á´ëÇб³ ¾È¾Ïº´¿ø ¿µ»óÀÇÇаú)"

ÈÞ½Ä 03¿ù 08ÀÏ 204,5È£ 15:20~15:40 Coffee Break ()

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 15:40~16:20 Far advanced thyroid cancer - How far can we try? ÀåÇ×¼®(¿¬¼¼ÀÇ´ë ¿Ü°ú)

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 16:20~16:40 ÀÇÇÐ ¿¬±¸¿¡¼­ÀÇ Generative AI¿Í Large Language Model: ÇöȲ°ú Àü¸Á Á¤±Ôȯ(¼º±Õ°ü´ëÇб³ »ï¼ºÀ¶ÇÕÀÇ°úÇпø)

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 16:40~17:00 °©»ó¼± ÀÇÇבּ¸¿¡¼­ÀÇ Large Language ModelÀÇ Àû¿ë »ç·Ê ¹Ú±â¼º(Àü³²ÀÇ´ë ÇÙÀÇÇаú)

±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 17:00~17:20 Prompt Engineering: ÀÇÇÐ³í¹® ÀÛ¼º¿¡¼­ÀÇ ChatGPT »ç¿ë Knowhow À̷οî(ÀÎÇÏÀÇ´ë ¿µ»óÀÇÇаú)

Åä·Ð 03¿ù 08ÀÏ 204,5È£ 17:20~17:30 Discussion ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2024-03-08""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-03-09
´ÙÀ½±Û (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-03-07
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
497 ¼­¿ï °æÈñ´ëÇб³º´¿ø 2018 KYUNG HEE SHOULDER SYMPOSIUM : 2018-09-08 0 1,517 2018-08-22
496 ´ë±¸ °æºÏ´ëÇб³º´¿ø Á¦ 3Â÷ °³¿øÀǸ¦ À§ÇÑ ´ëÇѺÎÁ¤¸ÆÇÐȸ ¿¬¼ö±³À° : 2018-09-07 0 749 2018-08-22
495 °­¿ø ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø NAFLD(non-alcoholic fatty liver disease) and Cardiometabolic Syndrome [7th Gangwon Heart Seminar 2018] : 2018-09-07 0 922 2018-08-22
494 ÀüºÏ ÀüÁÖ ¿¹¼öº´¿ø ´ëÇÑÀçÈ°ÀÇÇÐȸ È£³²Á¦ÁÖÁöȸ ÀçÈ° ½ÉÆ÷Áö¾ö : 2018-09-07 0 1,040 2018-08-22
493 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ¾È°ú ±Ý¿äÁý´ãȸ : 2018-09-07 0 850 2018-08-22
492 ¼­¿ï 2018³â °³¿øÀǸ¦ À§ÇÑ °­µ¿°æÈñ´ëÇб³º´¿ø ¼ÒÈ­±âÁúȯ ¿¬¼ö°­Á : 2018-09-06 0 683 2018-08-22
491 Ãæ³² ´Ü±¹´ëÇб³º´¿ø 2018³â Á¦3Â÷ ´ëÇѺ´¸®ÇÐȸ ´ëÀü¤ýÃæûÁöȸ: ÃÖ½ÅÀÇÇÐÁ¤º¸ Ư°­ ¹× º´¸®ÇÐ Áõ·Ê ¹ßÇ¥ : 2018-09-06 0 769 2018-08-22
490 ´ë±¸ ´ëÇѽŻý¾ÆÇÐȸ ´ë±¸°æºÏÁöȸ Áý´ãȸ : 2018-09-06 0 992 2018-08-22
489 Àü³² Á¦257Â÷ ´ëÇѳ»°úÇÐȸ ±¤ÁÖÀü³²Áöȸ Çмú´ëȸ : 2018-09-06 0 574 2018-08-22
488 °æ³² ´ëÇÑÇǺΰúÇÐȸ º£Ã¼Æ®º´ÀÇ ÃÖ½ÅÁö°ß¿¡ °üÇÏ¿© : 2018-09-06 0 717 2018-08-22
487 Ãæ³² °Ç¾ç´ëÇб³º´¿ø ´ëÇÑÇǺΰúÇÐȸ ÃæûÁöºÎÇÐȸ : 2018-09-06 0 897 2018-08-22
486 ´ë±¸ °è¸í´ëÇб³ µ¿»êÀÇ·á¿ø ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ Á¦234Â÷ °æºÏÁöȸ Áý´ãȸ : 2018-09-06 0 741 2018-08-22
485 °æ±â °¡Å縯´ëÇб³ ºÎõ¼º¸ðº´¿ø ´ëÇѺñ´¢±â°úÇÐȸ 2018 Á¦ 3Â÷ ÀÎõ.°æ±âÁöȸ Áý´ãȸ : 2018-09-06 2 1,474 2018-08-22
484 °æ³² ´ëÇÑÈäºÎ¿Ü°úÇÐȸ 2018³âµµ 3Â÷ ºÎ»ê¿ï»ê°æ³² ÈäºÎ¿Ü°ú Áý´ãȸ ¹× °­¿¬ : 2018-09-06 0 695 2018-08-22
483 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø À̺ñÀÎÈÄ°ú 2Çбâ Áö¿ªÀÇ»çÁý´ãȸ : 2018-09-06 0 532 2018-08-22
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷